CGI vs Edenred

10-Q Financial Filing Analysis for CGI (2026-07-29)

Corcept Therapeutics reported strong financial results for the second quarter ended June 30, 2026, generating net product revenue of $256.1 million, a 31.7% increase year-over-year. Growth was accelerated by the commercial launch of Lifyorli (relacorilant) in combination with nab-paclitaxel for platinum-resistant ovarian cancer, which contributed $47.6 million in debut quarterly sales alongside core hypercortisolism therapies. On the regulatory and legal front, Corcept resubmitted its relacorilant NDA for endogenous Cushing's syndrome with a PDUFA date set for December 17, 2026, while the Court of Appeals affirmed a non-infringement ruling in the Teva patent litigation and denied a rehearing en banc in July 2026.

• Q2 2026 net product revenue rose 31.7% year-over-year to $256.1 million, bolstered by $47.6 million in initial sales from newly launched Lifyorli.
• Corcept resubmitted its New Drug Application (NDA) for relacorilant in endogenous Cushing's syndrome on June 17, 2026, establishing an FDA PDUFA target action date of December 17, 2026.
• The Court of Appeals affirmed a District Court ruling of non-infringement in the Teva patent litigation, with a petition for rehearing en banc denied in July 2026.

CGI Prices C$500 Million Senior Notes Offering

CGI Inc. has priced a private offering of C$500 million in senior unsecured notes, split equally between 3.25-year and 4.75-year maturities, with interest rates of 4.195% and 4.484% respectively. The offering is expected to close around September 14, 2026, and the net proceeds of approximately C$497.3 million will be used to repay existing indebtedness and for general corporate purposes. The notes are being offered in Canada on a private placement basis through a syndicate of agents led by major Canadian financial institutions including Scotiabank, Desjardins, BMO, CIBC, National Bank, RBC, and TD Securities. This financing move is part of CGI's capital management strategy to optimize its debt structure, reflecting the company's strong market position and liquidity management.

• CGI priced C$500 million in senior unsecured notes, split into two series of C$250 million each.
• The notes carry interest rates of 4.195% (3.25-year) and 4.484% (4.75-year).
• Net proceeds of ~C$497.3 million will be used for debt repayment and general corporate purposes.

CGI to release third quarter fiscal 2026 results on July 29

CGI to release third quarter fiscal 2026 results on July 29

Actionable Raises $10M to Build Causal AI for Customer Service

Actionable, a Paris-based AI-driven customer intelligence startup, has raised €8.5 million (approximately $10 million) in a funding round led by Hi inov, with participation from existing investor Axeleo Capital. Founded in 2024 by co-CEOs Nans Thomas and Nicolas Rieul, Actionable integrates data from CRMs, CDPs, transaction systems, and web analytics into a unified customer data model. The platform automatically reconstructs customer journeys to score entire customer bases daily on churn, satisfaction, complaint risk, and repeat purchase likelihood, providing causal insights for sectors like retail, financial services, insurance, transport, energy, telecoms, and automotive. Notable clients include Carrefour, SNCF, Engie, and Edenred. The funding will support US market entry via reseller partners, scaling the platform, hiring in product, engineering, and sales, and R&D in causal AI and deterministic modeling.

• Actionable raised €8.5 million ($10 million) in a funding round led by Hi inov, with participation from Axeleo Capital.
• Founded in 2024 by Nicolas Rieul and Nans Thomas, the platform predicts churn, satisfaction, complaint risk, and repeat purchases.
• The funding will support US expansion via reseller partners, sales hiring, and development of causal AI features.

Edenred updates financial calendar: Q3 2026 revenue on 21 October 2026

The previous agenda item 'Résultats semestriels 2026' on 23 July 2026 has been replaced by 'Chiffre d’affaires du troisième trimestre 2026' on 21 October 2026.

Edenred announces half-year results 2026 scheduled for July 23, 2026

23 juillet 2026 : Résultats semestriels 2026